Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

Yumanity Therapeutics logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.89
52-Week Range
N/A
Volume
6,790 shs
Average Volume
473,083 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMTX Stock News Headlines

JSPR Jasper Therapeutics, Inc.
Cara Therapeutics Inc CARA
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.
Yumanity Therapeutics Inc.
See More Headlines

YMTX Stock Analysis - Frequently Asked Questions

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to analyst estimates of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yumanity Therapeutics investors own include NIO (NIO), Arch Therapeutics (ARTH), Aytu BioPharma (AYTU), Clarus Therapeutics (CRXTQ), Ford Motor (F), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/12/2021
Today
8/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMTX
CIK
1445283
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.50 million
Net Margins
-660.61%
Pretax Margin
-660.61%
Return on Equity
-263.34%
Return on Assets
-107.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$4.84 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.28 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
10,856,000
Free Float
9,504,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
0.32

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:YMTX) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners